A petition has been filed to centralize all federal lawsuits involving heart problems from Androgel for coordinated proceedings as multidistrict litigation. According to the plaintiffs’ motion to transfer, they prefer that the cases are consolidated in the U.S. District Court for the Northern District of... Read More

The latest AndroGel lawsuit was filed in Chicago on March 12, 2014 against AbbVie, Inc and its parent company, Abbot Laboratories, producers and marketers of AndroGel, a testosterone therapy popularly marketed to treat “Low T.” In Dula v. AbbVie, Inc. et al (1:14-CV-01726), the plaintiff,... Read More

Increased skepticism and closer scrutiny of the benefits and risks of testosterone therapy is beginning to emerge in the wake of several research reports highlighting their potential danger, according to a recent New York Times story by Roni Caryn Rabin. However, given the wild popularity these... Read More

In the midst of growing concern about the safety of widely popular testosterone therapy drugs, consumer advocacy watchdog group Public Citizen has just petitioned the U.S. Food and Drug Administration to place bold, stark labeling on such medications alerting users to the increased risk of... Read More

In response to two recent studies of the possible connection between testosterone therapy and an increased risk of heart attack, stroke and death, the U.S. Food and Drug Administration (FDA) has announced that it will conduct a formal assessment and report on its conclusions and... Read More

In the most recent study linking testosterone therapy to heart problems, researchers found a correlation between taking testosterone drugs and increased rates of heart attack both in men older than 65 and men younger than 65 with a known risk of heart problems.  The study,... Read More